v3.25.2
Segment Reporting - Summary of Financial Information of Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Total R&D program expense $ 61,030   $ 36,259   $ 102,489 $ 66,905
Equity-based compensation expense         19,261 18,760
Loss from operations (75,798)   (50,027)   (130,794) (93,016)
Interest income 5,924   8,071   12,504 13,764
Other income (expense), net (181)   (72)   (266) (116)
Net loss (70,055) $ (48,501) (42,028) $ (37,340) (118,556) (79,368)
Net loss attributable to noncontrolling interests 0   0   0 (192)
Net Income (Loss) (70,055)   (42,028)   (118,556) (79,176)
Velinotamig [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 10   0   10 0
Operating Segments [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 27,008   25,144   54,669 46,142
Equity-based compensation expense 9,887   10,533   19,261 18,760
R&D personnel and operations 9,741   7,236   19,572 13,724
General and administrative personnel 3,335   3,601   6,824 7,553
License agreement obligations 20,115   25   20,153 50
Other segment expenses [1] 5,712   3,488   10,315 6,787
Loss from operations (75,798)   (50,027)   (130,794) (93,016)
Interest income 5,924   8,071   12,504 13,764
Other income (expense), net (181)   (72)   (266) (116)
Net loss (70,055)   (42,028)   (118,556) (79,368)
Net loss attributable to noncontrolling interests 0   0   0 (192)
Net Income (Loss) (70,055)   (42,028)   (118,556) (79,176)
Operating Segments [Member] | CLN-978 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 5,393   4,458   10,066 5,961
Operating Segments [Member] | CLN-619 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 7,317   7,329   13,435 11,615
Operating Segments [Member] | Zipalertinib [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 6,001   7,226   16,161 15,514
Operating Segments [Member] | CLN-049 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 4,898   1,686   8,793 3,162
Operating Segments [Member] | CLN-617 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 1,403   953   3,196 1,965
Operating Segments [Member] | CLN-418 [Member]            
Segment Reporting Information [Line Items]            
Total R&D program expense 0   2,037   0 5,109
Operating Segments [Member] | Early-stage programs [Member            
Segment Reporting Information [Line Items]            
Total R&D program expense $ 1,986   $ 1,455   $ 3,008 $ 2,816
[1] Other segment expenses for the three and six months ended June 30, 2025 and 2024 include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; marketing expenses; depreciation; and other operating costs.